Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 3/20 | 0.35 |
| ▸ | ACACB | O00763 | 2/20 | 0.33 |
| ▸ | ACACA | Q13085 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
| ▸ | MAP4K1 | Q92918 | 3/20 | 0.32 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.32 |
| ▸ | HIPK2 | Q9H2X6 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.31 |
| ▸ | LATS1 | O95835 | 1/20 | 0.31 |
| ▸ | LATS2 | Q9NRM7 | 1/20 | 0.31 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.30 |
| ▸ | KLK1 | P06870 | 1/20 | 0.30 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31473624 | 0.92 | SYK (0.33) | NNMTSYK | |
| SCHEMBL31473597 | 0.87 | TNF (0.34) | ACACBACACASYK | |
| SCHEMBL31473604 | 0.82 | NNMT (0.33) | NNMT | |
| SCHEMBL31474009 | 0.82 | LCK (0.35) | SYKMAP4K1OPRM1OPRL1 | |
| SCHEMBL31474005 | 0.81 | PARG (0.38) | SYKMAP4K1HIPK2OPRM1OPRL1 | |
| SCHEMBL31165187 | 0.80 | SYK (0.33) | ACACBACACASYKCSNK2A1HIPK2 | |
| SCHEMBL31473833 | 0.80 | NNMT (0.30) | NNMT | |
| SCHEMBL31473731 | 0.80 | NNMT (0.30) | NNMT | |
| SCHEMBL31473640 | 0.79 | — | — | |
| SCHEMBL30698968 | 0.78 | NNMT (0.32) | NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | SUNDANCE BIOSCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025906-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | TYK2, JAK1, JAK3 | NNMT 1091/4885ACACB 3491/4885ACACA 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.